{
    "ticker": "VRNA",
    "name": "Verona Pharma plc",
    "description": "Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Founded in 2006 and headquartered in London, UK, Verona Pharma is committed to addressing unmet medical needs in respiratory medicine, particularly with its lead product candidate, ensifentrine, a dual inhibitor of the enzymes dipeptidyl peptidase I (DPP1) and DPP4. This innovative therapy is being developed for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The company's pipeline also includes other drug candidates aimed at treating various respiratory disorders. Verona Pharma aims to provide significant advancements in patient care through its research and development initiatives, emphasizing the importance of effective therapeutic solutions in managing chronic respiratory diseases. The company is committed to ethical practices in clinical development and seeks to engage with healthcare professionals to ensure that its products meet the needs of patients and caregivers alike. With a strong focus on innovation, Verona Pharma is well-positioned to make impactful contributions to the field of respiratory medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2006",
    "website": "https://www.veronapharma.com",
    "ceo": "David Zaccardelli",
    "social_media": {
        "twitter": "https://twitter.com/veronapharma",
        "linkedin": "https://www.linkedin.com/company/verona-pharma-plc/"
    },
    "investor_relations": "https://www.veronapharma.com/investors/",
    "key_executives": [
        {
            "name": "David Zaccardelli",
            "position": "CEO"
        },
        {
            "name": "Richard A. G. C. Jones",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Respiratory Therapies",
            "products": [
                "Ensifentrine"
            ]
        }
    ],
    "seo": {
        "meta_title": "Verona Pharma plc | Innovative Respiratory Therapies",
        "meta_description": "Learn about Verona Pharma plc, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for respiratory diseases. Explore our lead product, ensifentrine, and our commitment to improving patient outcomes.",
        "keywords": [
            "Verona Pharma",
            "Respiratory Diseases",
            "Biopharmaceuticals",
            "COPD",
            "Ensifentrine"
        ]
    },
    "faq": [
        {
            "question": "What is Verona Pharma known for?",
            "answer": "Verona Pharma is known for its innovative therapies for respiratory diseases, particularly its lead product candidate, ensifentrine."
        },
        {
            "question": "Who is the CEO of Verona Pharma?",
            "answer": "David Zaccardelli is the CEO of Verona Pharma plc."
        },
        {
            "question": "Where is Verona Pharma headquartered?",
            "answer": "Verona Pharma is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Verona Pharma's main products?",
            "answer": "Verona Pharma's main product is ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD)."
        },
        {
            "question": "When was Verona Pharma founded?",
            "answer": "Verona Pharma was founded in 2006."
        }
    ],
    "competitors": [
        "REGN",
        "GILD",
        "AMGN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRNA",
        "ABBV"
    ]
}